Having cancer is inevitably a painful experience. While background pain medication is often used to alleviate the occurrence of pain, sometimes the onset of pain can be unpredictable and sudden. Breakthrough cancer pain, also known as BTCP, is characterized by this very concept. BTCP is the onset of intense pain, which can peak in severity over three to five minutes despite the active nature of background pain medication.
One company that has recently developed a proprietary product to counter the effects of BTCP is Insys Therapeutics, Inc. (NASDAQ:INSY). In January 2012, Insys received marketing approval from the U.S. Food and Drug Administration for its proprietary drug Subsys. Subsys is a single-use product that delivers a dose of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|